P2X 7-receptor binding in new-onset and secondary progressive MS – a [11C]SMW139 PET study




Lehto, Jussi; Aarnio, Richard; Tuisku, Jouni; Sucksdorff, Marcus; Koivumäki, Esa Mikko; Nylund, Marjo; Helin, Semi; Rajander, Johan; Danon, Jonathan; Gilchrist, Jayson; Kassiou, Michael; Oikonen, Vesa; Airas, Laura

Publisher Springer Nature

2024

EJNMMI Research

EJNMMI Research

123

14

2191-219X

DOIhttps://doi.org/10.1186/s13550-024-01186-3

https://doi.org/10.1186/s13550-024-01186-3

https://research.utu.fi/converis/portal/detail/Publication/477194843



Background

PET imaging of activated microglia has improved our understanding of the pathology behind disability progression in MS, and pro-inflammatory microglia at ‘smoldering’ lesion rims have been implicated as drivers of disability progression. The P2X 7R is upregulated in the cellular membranes of activated microglia. A single-tissue dual-input model was applied to quantify P2X 7R binding in the normal appearing white matter, perilesional areas and thalamus among progressive MS patients, healthy controls and newly diagnosed relapsing MS patients.

Results

Overall, tracer uptake in the MS brain was not significantly higher compared to HCs. In the 3 mm perilesional rim of all T1 lesions, tracer binding was higher among relapsing patients compared to progressive patients. Tracer binding was higher in males compared to females. Disease duration correlated with tracer binding in the normal appearing white matter. Age correlated negatively with tracer binding in the perilesional rims.

Conclusions

Even as binding estimates obtained with the dual-input model were consistent with the expected distribution of P2X 7Rs in the MS brain, the small free fraction of the parent tracer may limit its accuracy and applicability, and binding estimates between subjects were highly variable. Conclusive evidence for the applicability of [11C]SMW139 to detect MS-related diffuse smoldering inflammation was not obtained.


This work was supported by a grant from the National Multiple Sclerosis Society, The Jane and Aatos Erkko Foundation, The Research Council of Finland (decision number: 330902), the Sigrid Juselius Foundation, State research funding of the Turku University Hospital expert responsibility area, Finnish Governmental Research Funding (VTR) for Turku University Hospital, and the InFLAMES Flagship Programme of The Research Council of Finland (decision number 337530).


Last updated on 2025-27-01 at 19:54